Background: Glycan-binding proteins are widely distributed in human and play an essential
role in biological processes. Their involvements in inflammatory and immune responses make it
increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments
of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding
proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical
investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being
approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies
have provided great promises in therapeutic targeting of more glycan-binding proteins for treating
multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.